MCM
SLDB icon

Moore Capital Management’s Solid Biosciences SLDB Stock Holding History

Moore Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03M Buy
603,472
+278,723
+86% +$2.11M 0.09% 197
2026
Q1 		$2.34M Buy
+324,749
New +$2.09M 0.05% 262

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Moore Capital Management's SLDB Position: Q2 2026 in Review

Moore Capital Management increased its Solid Biosciences (SLDB) stake by 86% in Q2 2026, buying an estimated $2.11M and bringing the position to 603,472 shares worth $6.03M. The position accounts for 0.09% of the portfolio, ranked #197.

Moore Capital Management first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Moore Capital Management held 603,472 shares of Solid Biosciences worth $6.03M as of Q2 2026.
  • Moore Capital Management bought 278,723 Solid Biosciences shares in Q2 2026, an estimated $2.11M.
  • Solid Biosciences made up 0.09% of Moore Capital Management's portfolio in Q2 2026, its #197 holding.
  • Moore Capital Management first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.